The FDA now acknowledges at least 10 American children died “after and because of” receiving Covid-19 vaccines, according to a memo from agency officials that was reviewed by a national newspaper.

Federal regulators have concluded that at least 10 children died in connection with Covid-19 vaccinations, and that finding is being described inside the agency as shocking and consequential. Agency leadership, led by Dr. Vinay Prasad, flagged the deaths in an internal memorandum that, for now, has not been posted publicly.

Questions about vaccine safety for young people have been raised for years by parents and several physicians, and this internal memo appears to give weight to those concerns. The document was seen by reporters at a major news outlet, which published details from the memo even though the agency has not released it in full.

Within the memo, the agency’s vaccine division wrote, “The director of the Food and Drug Administration’s vaccine division said in a memo to agency staff on Friday that a review had found that at least 10 children had died “after and because of” getting a Covid vaccination.” That statement is followed by another line that reads, “Dr. Vinay Prasad, the director, suggested in the memo that the deaths were related to myocarditis, or inflammation of the heart muscle.”

The memo, as reported, also leaves out important specifics that would help the public evaluate the claim: “The memo, obtained by The New York Times and not publicly released, did not provide details such as the ages of the children, whether they had any other health problems or how the agency determined the vaccine-death link. Nor did it disclose the maker of the vaccines involved.” Those are glaring gaps for anyone trying to weigh risk.

Inside the memorandum, Dr. Prasad calls the finding “a profound revelation,” and he adds, “For the first time, the U.S. F.D.A. will acknowledge that Covid-19 vaccines have killed American children.” Those exact words undercut years of public assurances that serious vaccine harms in children were vanishingly rare.

Officials now say they will reassess how they approve vaccines. One account of the agency discussion notes that leadership plans to take a tougher stance on approval standards, pushing manufacturers to provide more data on safety and benefit before expanding recommendations to children and teens.

That same account includes this passage: “Vinay Prasad, an FDA official whose approach to vaccine policy has been championed by Health Secretary Robert F. Kennedy Jr., told agency officials that the FDA will rethink its framework for annual flu shots, examine whether Americans should be receiving multiple vaccines at the same time, and require vaccine makers to show far more data to prove the safety and value of their products.” Those are significant procedural shifts if they stick.

The drive to demand more data and to reexamine simultaneous dosing responds directly to worries about cardiovascular inflammation after mRNA shots in younger males. The memo’s apparent link to myocarditis will intensify pressure on the FDA to explain how it reached conclusions and what signals it will use to downgrade or restrict use in minors.

Parents and clinicians will want transparent information about each case: age, underlying conditions, timing of symptoms after vaccination, autopsy or review findings, and the manufacturer involved. Without those details, it’s hard for the public to assess the magnitude and nature of the risk or to balance it against the risks of Covid infection itself.

Regulators signaling a more cautious approval path could change how vaccines are recommended and rolled out in schools and pediatric practices. If the agency demands larger, longer safety datasets and stricter evidence that benefits outweigh harms in children, vaccine makers may face higher hurdles before they can expand pediatric use.

The memo and the internal policy shift mark a new moment for federal vaccine oversight, one that will be watched closely by parents, doctors, and policymakers. The agency’s next steps — whether to release the full memo, open a public review, or revise its approval standards — will determine how this finding affects future immunization guidance and public confidence.